I know biotech companies are not sexy right now, but this is one...

I know biotech companies are not sexy right now, but this is one to keep an eye on. They have an interesting portfolio of products in phase II trials plus a production arm and some great ongoing research. Not many shares out there either...
AnnaP

This announcement just outANADIS LIMITED 2002-10-07 ASX-SIGNAL-G

HOMEX - Melbourne

+++++++++++++++++++++++++
Anadis Limited is pleased to announce that we have joined with the
Department of Defence to further develop a breakthrough technology
that has potential to provide effective short-term protection for
military personnel against a range of biological warfare threats,
including anthrax and plague, as well as protecting civilian
emergency workers against diseases such as tuberculosis and
Legionnaire's disease.

Anadis laboratory trials have shown the technology is highly
successful in protecting the lungs against a Yersinia bacterium
closely related to the species that causes plague. Anadis has lodged
a provisional patent on the discovery.

This is a revolutionary discovery: the bacteria that cause plague and
anthrax have been very difficult to vaccinate against or to treat
with antibiotics because they survive within immune cells in the
lungs.

The Department of Defence has asked Anadis to work with it in a joint
research program that combines Anadis' binding protein technologies,
bioshielding technologies and protective respiratory technologies
with the expertise of scientists from the Defence Science and
Technology Organisation.

Anadis and Defence scientists are now designing the joint project and
will work together to produce assays, diagnostics and therapies of
interest to the Australian Defence Force. The technologies are also
highly likely to be of interest to Australia's military allies.

Anadis also believes that the technology could have other potential
uses in the civilian area, and is currently exploring a number of
other applications.

Additionally, Anadis is currently involved in negotiating with The
Development Centre for Biotechnology in Taiwan the potential for
Anadis' technologies to be applied for the potential treatment of
Enterovirus 71 - a virus prevalent in children in Asia.


C Graham
MANAGING DIRECTOR & CEO


For further information Contact:

Conor Graham or Dr Grant Rawlin
Telephone : 03 9358 6388
Facsimile: 03 9358 6399
Email: [email protected]